Nav: Home

Study provides new clues to leukemia resurgence after chemotherapy

June 02, 2016

(WASHINGTON - June 2, 2016) - For the first time, researchers have discovered that some leukemia cells harvest energy resources from normal cells during chemotherapy, helping the cancer cells not only to survive, but actually thrive, after treatment.

The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), focuses on acute myeloid leukemia (AML), a cancer of the blood and bone marrow that is the most common type of acute leukemia in adults. Nearly 20,000 U.S. adults are diagnosed with AML each year, and another 10,400 die from it annually, according to the American Cancer Society. Although chemotherapy treatments are often initially successful against this type of cancer, relapse occurs in about two-thirds of treated patients, often resulting in death.

The researchers found that leukemia cells are capable of stealing organelles known as mitochondria from stromal cells, non-cancerous connective tissue cells found in bone marrow and other organs. These stolen mitochondria give an energy boost to the surviving cancer cells that helps fuel the cancer's rebound, they explain.

"There are multiple mechanisms for resistance to chemotherapy, and it will be important to target them all in order to eliminate all leukemic cells," said Jean-François Peyron, PhD, team leader at the Centre Méditerranéen de Médecine Moléculaire (C3M) in Nice, France. "Targeting this protective mitochondrial transfer could represent a new strategy to improve the efficacy of the current treatments for acute myeloid leukemia."

The team conducted their experiments using cell cultures and mice, examining cells under the microscope. They found that while almost all cancer cells died when exposed to chemotherapy drugs, some stayed alive. Those that survived issued a "mayday" signal that tricked nearby non-cancerous cells to yield their mitochondria to the leukemia cell, thus strengthening the cancer cell.

"Mitochondria produce the energy that is vital for cell functions," said Emmanuel Griessinger, PhD, principal investigator of the study. "Through the uptake of mitochondria, chemotherapy-injured acute myeloid leukemia cells recover new energy to survive. It's like getting new batteries, or refueling during a pit stop."

The leukemia cells were found to increase their mitochondria mass by an average of 14 percent. This increase in mitochondria led to a 1.5-fold increase in energy production and significantly better survival rates. That is, the leukemia cells that have a high level of mitochondria are also more resistant to the chemotherapy.

The researchers observed the phenomenon in several types of leukemia cells, most notably those known as leukemia-initiating cells, which are considered to be responsible for the cancer's resurgence after treatment. Authors say this finding may explain why it is hard to treat some cancers.

Researchers believe these findings offer new hope for developing better treatments for AML. If researchers can find a way to interrupt the "mayday" signal or otherwise interfere with the transfer of mitochondria, that knowledge could lead to chemotherapy drugs that would reduce the risk of relapse.

The study has clear implications for AML, but it may also shed light on other cancer types. It is likely that similar mechanisms may be at play in other blood cancers that involve the bone marrow, and it is also possible that the mechanism could be found in solid tumors as well, according to the researchers.

According to the study authors, the next important step will be to identify the mechanism underlying the transfer of mitochondria to AML.
-end-
Blood, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders.

ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology. Follow @BloodJournal on Twitter.

American Society of Hematology

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...